Sense Biodetection Raises $50M in Series B Financing toward COVID-19 Test, Dx Portfolio

Sense Biodetection has completed a $50 million Series B financing, with the molecular diagnostics company saying it will use the proceeds to accelerate the launch of its Veros COVID-19 test, and further develop a portfolio of instrument-free, rapid molecular tests.

Those tests will be based on Sense’s Veros platform, which is designed to detect a variety of deadly and costly diseases by applying rapid molecular amplification technology.

The platform is intended to underpin a new class of rapid molecular diagnostic tests that emulate the performance of central laboratory PCR testing, but are disposable and easy-to-use since they do not need an accompanying instrument or reader.

As a result, Sense says, Veros diagnostics can be used beyond traditional healthcare settings–enabling better access, outcomes, and value for patients and providers.

Continue reading…

Share on facebook
Share
Share on twitter
Tweet
Share on linkedin
Share

More To Explore